Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
A recent study found one in five people with HIV should be assessed for fatty liver, and 1 in 10 should be referred to a liver specialist.
Gastrointestinal cancers conference emphasizes patient quality of life.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
The injectable hormone was approved to treat excess abdominal fat in those with antiretroviral-associated lipodystrophy.
The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Researchers have identified biomarkers that can identify NAFLD and rule out advanced fibrosis.
Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.
The number of HIV-positive Medicare recipients with liver disease is rising, almost entirely as a result of NAFLD
Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.